At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 99 enrolled

Drug / intervention

Concurrent chemotherapy +1 moredrug

Likely dose

Concurrent chemotherapy 25mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02573506

NCT02573506Phase 2Completed

Compare CT.gov

A Prospective Phase Ⅱ Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer

Sun Yat-sen University·interventional·Posted Oct 9, 2015·Updated Apr 14, 2020

In Brief

A Phase 2 clinical trial evaluating split-course radiotherapy and Concurrent chemotherapy for Non-small Cell Lung Cancer. Completed, enrolled 99 participants across 1 site.

Detailed Summary

This Phase II study is to determine the efficacy of split-course irradiation with concurrent chemotherapy in locally advanced none-small cell lung cancer patients.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsNon-small Cell Lung Cancer

CountriesChina

Collaborators--

Timeline

Phase 2CompletedFinished

20162017201820192020202120222023202420252026

Enrollment StartAug 2015

First PostedOct 2015

Primary CompletionMar 2020

TodayJul 2026

First PostedOct 9, 2015

Enrollment StartAug 1, 2015

Primary CompletionMar 1, 2020

TodayJul 2, 2026

Enrollment to primary: 4.6 yearsPosted 10.7 years ago

Interventions

split-course radiotherapyradiation

Patients are irradiation at a palliative dose in the initial course: 51Gy/17f to PTV-GTV. The disease is re-evaluated three weeks after the end of the initial course using CT. The patient without disease progression according to the RECIST criteria and had a recovery of lung function should get the additional boost. In the second course, the tumor is repositioned and scanned. The residual tumor is then treated with the second course of radiotherapy. A dose of 15-18 Gy/5-6f is delivered to the residue tumor.

Concurrent chemotherapydrug

Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.